Navigation Links
Medarex Announces 2007 Fourth Quarter and Year End Financial Results
Date:2/26/2008

f Clinical

Oncology (ASCO);

-- Announcing the receipt of a milestone payment from our licensing

partner, Novartis Pharma AG, in connection with the progress of ACZ885,

a fully human anti-IL-1beta antibody in Phase 3 development for the

treatment of Muckle Wells' Syndrome that was generated using Medarex's

UltiMAb(R) technology;

-- Announcing the receipt of a milestone payment from our licensing

partner, Amgen, Inc., for the advancement of an antibody into a Phase 2

clinical trial;

-- Filing the IND with the FDA for MDX-1401, a fully human second-

generation anti-CD30 antibody, in development for the treatment of

CD30-positive lymphomas;

-- Announcing the IND filing by licensing partner ImClone Systems

Incorporated for IMC-3G3, a fully human antibody that targets platelet-

derived growth factor receptor alpha for the treatment of cancer;

-- Announcing the initiation of a Phase 1 clinical trial of MEDI-545, a

fully human antibody targeting interferon-alpha, for the treatment of

psoriasis by Medarex's partner, MedImmune, Inc.;

-- Entering into separate collaboration agreements with Mitsubishi Pharma

Corporation (a subsidiary of Mitsubishi Chemical Holdings Corporation),

Organon (now part of Schering-Plough), and Compugen Ltd. to develop

fully human antibodies for the treatment of cancer and/or autoimmune

diseases;

-- Announcing the award of up to an additional $13.9 million of government

funding to Medarex's partner, PharmAthene, Inc., towards the

development of Valortim(TM) for use as an anti-toxin therapeutic to

prevent and treat inhalation anthrax infections; and

-- Adding approximately $152 million to our cash resources in 2007 through

the sale of approximately 2.6 million shares of Genmab A/S common

stock.

"We enter
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Present at the JPMorgan Small/Mid Cap Conference
5. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
6. Grupo Casa Saba Announces Fourth Quarter 2007 Results
7. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
8. Reproductive Medicine Associates of Texas Announces Open House in San Antonio
9. WallSt.net (www.WallSt.net) Announces Upcoming Interview With Chairman and CEO of flexSCAN, Inc.
10. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
11. Thomson Healthcare Announces Enhancements to Order Sets Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage skin ... the first provider of Exilis non-surgical fat reduction in New York. Due to ... a large International clientele. Many patients travel to New York to get their ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... Mountain View, CA (PRWEB) , ... July 31, 2015 , ... ... hand for the athletes, judges, media, and VIPs at the 2015 Vans US Open ... best-tasting organic coconut water that can claim “no added sugar” on the market, is ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... According ... and cosmetic experts gathered to see if they could reach a consensus on the ... breast augmentation and facelifts. Overall, the group reached 90 percent consensus on a series ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Learn How Their Employee Health Benefit Plans Stack ... owners and human,resource executives grappling with ways to ... effective found out how their plans,compare to others ... Scott Rappoport, a 25-year veteran of the employee ...
... Band Surgery Performed Each Month in UK, ... LONDON, February 1 Today saw the launch of ... and support to people considering obesity surgery. To,coincide with ... survey reveal,widespread confusion over the causes of obesity in ...
... aren,t getting preventive treatments , , THURSDAY, Jan. 31 ... in hospitals worldwide risk developing dangerous blood clots ... treatments that could prevent the condition, a large ... been recognized to be one of the most ...
... Placement of IVIS Systems -, HOPKINTON, Mass., ... CALP ) today announced the shipment of the ... of 2007.,Introduced in 2000, the IVIS molecular imaging ... biological drug,discovery and development research on small living ...
... House Office of Management and Budget evaluates research at ... using the Program Assessment Rating Tool (PART), a set ... their programs, including whether they can measure and demonstrate ... OMB rates research programs as effective, ineffective, or somewhere ...
... Michael J. Fitzpatrick,executive director of the National ... statement:, A media circus and reckless speculation ... Britney Spears and her family. Professional ethics,require that ... treated,individuals not presume to diagnose them. A person,s ...
Cached Medicine News:Health News:Key to Attracting and Retaining Quality Employees: Benefits 2Health News:Key to Attracting and Retaining Quality Employees: Benefits 3Health News:Lose Weight Gain Life: New Website to Help People Seeking Information on Obesity Surgery 2Health News:Lose Weight Gain Life: New Website to Help People Seeking Information on Obesity Surgery 3Health News:Hospital Patients' Blood Clot Risk High 2Health News:Hospital Patients' Blood Clot Risk High 3Health News:Caliper Life Sciences Ships 500th IVIS Imaging System 2Health News:Changes needed in how federal government evaluates efficiency of research at EPA, other agencies 2Health News:Britney Spears: Let's Talk About All of Us 2
(Date:7/31/2015)... HILL, N.C. , July 31, 2015 /PRNewswire/ ... product success in the biopharmaceutical market. Patients are ... process of selecting and switching therapies. This shift ... is pushing marketers, efforts toward patient-focused marketing. ... patient engagement, marketers have learned it,s important to ...
(Date:7/31/2015)... HILL, N.C. , July 31, 2015  In ... of customers who are increasingly mobile, increasingly connected, and ... a growing variety of customer interaction channels and tools ... technology, including social media. According to ... the over the counter (OTC) segment in a call ...
(Date:7/31/2015)...  Seeger Weiss LLP is reporting that on July 13, ... to C.R. Bard, the manufacturer of Inferior vena cava ... violations the agency found at two of Bard,s facilities. Bard ... cited them during Inspectional Observations that occurred on November 18, ... AZ , location and on October 6, 2014, through ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... of its Proprietary Technology to Provide Accurate, Fully ... 34th Annual ISCE MeetingSANTA CLARA, Calif., March 31 ... cardiac diagnostic and services company, today announced that ... abstracts and discuss applications for its proprietary technology ...
... published in the Journal of Medicinal Food, ... (1/3 ounce) of "Sun Chlorella A" daily resulted in ... and fasting blood glucose levels.For a 12-week period, 34 ... each morning and evening. Seventeen subjects were healthy; ...
Cached Medicine Technology:NewCardio Leadership to Present Two Abstracts at ISCE Conference 2NewCardio Leadership to Present Two Abstracts at ISCE Conference 3NewCardio Leadership to Present Two Abstracts at ISCE Conference 4First Human Study to Show 'Sun Chlorella A' Supports Heart Health 2
... Whether for bypass grafting or creation of ... placed tissue tunnel is of the utmost ... is the answer for those seeking a ... configuration minimizes the risk of twisting or ...
... Cardiovascular Patch utilizes advanced fluoropolymer ... around penetrating suture and decrease ... much as 88 percent. This ... retention, multi-directional strength and low ...
... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
... GORE-TEX Stretch Vascular Grafts have met ... vascular procedures. Recognized for exceptional performance ... endorsement of renowned surgeons worldwide. These ... and the spread of infection, and ...
Medicine Products: